Harbin Pharmaceutical Group Co., Ltd. in 2005 through the restructuring to increase their investment from the state-controlled joint venture. With two in the Shanghai Stock Exchange listed public company (ie, Harbin Pharmaceutical Group Co., Ltd. and Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.) and 27 wholly-owned, holding and joint stock companies. Total registered capital of 3.7 billion yuan, total assets of 14.65 billion yuan, equity 8.96 billion yuan. The current number of employees 18,382 people, groups affiliated pharmaceutical companies households 12. Harbin Pharmaceutical Group financial
pharmaceutical manufacturing, trade, scientific research in one, covering the main business of antibiotics, chemical pharmaceutical preparations, non-prescription medicines and health food, medicine, bio-engineering drugs, animal vaccines and veterinary drugs, pharmaceutical distribution field of seven industry . Total production of bulk drugs and antibiotics, injection, medicine, Chinese medicine powder for injection, comprehensive preparations and other seven series, 20 kinds of dosage forms, more than 1,000 varieties. With annual production capacity of 13,000 tons of antibiotics and intermediates, medicine powder for injection 3 billion, 400 million water-pin, 20 billion tablets, capsules 12.5 billion, oral 3 billion, 45 billion birds animal vaccines copies. Harbin Pharmaceutical Group's production companies have all passed the GMP certification, the major distribution companies have passed the GSP certification, Harbin Pharmaceutical Factory, the three precise pharmaceutical companies and some other group, which passed the ISO9001, ISO14001, OHSAS18001 international management system certification. Harbin Pharmaceutical Group in China more than 30 major urban areas to establish more than 130 sales offices, and has more than 200 retail chain pharmacies, covering the wide range of features and strong marketing network.
Years, the Harbin Pharmaceutical Group, adhering to the "authentic to do drugs, do kind business" business purposes, rapid increases in market share, business has been expanding, some of the products into Europe, Asia, Africa, the North American market, the annual export earned $ 100 million. With "to working together to Clipsal, to keep Germany" business philosophy, innovation and active implementation of brand strategy, the community has won universal praise. Authoritative assessment of brand value by domestic institutions - Assets Appraisal Co., Ltd. Beijing brand value assessment of Harbin Pharmaceutical Group, the brand value of 16.062 billion yuan to become one of the most valuable brand medicine. Harbin Pharmaceutical Group currently has a "HaYao", "three fine", "World a" "Ca Ca" and other four known trademarks in China, creating the industry and the Northeast the most.
In establishing a strong brand, full use of Harbin Pharmaceutical Group, the brand for the company accumulated a wealth of resources and conditions, with greater spirit into the work of independent innovation. Companies to invest 100 million yuan to build new drug R & D system. Around its 1996 level enterprise technical centers established and post-doctoral workstations, creating a bio-engineering, antibiotics, pharmaceutical preparations, modern medicine, OTC drugs and health food, animal vaccines and veterinary drugs in six technical platform. Through this focus on six platforms have an advantage to their own core technology, the core industry started research and development, also marks the Harbin Pharmaceutical's drug development shift from the previous arbitrary professional, accelerated by the full imitation to innovation shift the direction of the pace of R & D .
After years of development, Harbin Pharmaceutical Group to continuously improve the self-developed system and the gradual growth of the research team, with its powerful brands together constitute the company off the wings. With this powerful brand, Harbin Pharmaceutical Group's independent research and development system was sufficient room to grow; the company's brand building from the self-developed system with a strong force there to support.
Ministry of Commerce published in 2005-2006, China's largest 500 foreign invested enterprises, the Harbin Pharmaceutical Group ranked No. 88 in 2006, won the first hundred Chinese pharmaceutical industry, in 2007 won the "China Most Admired Companies "in 2008, the fourth hundred of the pharmaceutical industry, ranking China first; Harbin Pharmaceutical Group Holding companies - Harbin Pharmaceutical Group Co., Ltd. was named the Global Chinese medicine hundred titles; Harbin Pharmaceutical Group Holding listed companies - Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. ranked the best growth of listed companies, 2006 50 top pharmaceutical companies in 2007, the SSE Corporate Governance Sector selected sample shares.
Harbin Pharmaceutical Group in China more than 30 major urban areas to establish more than 130 sales offices, and retail chain has more than 1250 pharmacies, covering the wide range of features and strong marketing network. Part of the products into Europe, Asia, Africa, the North American market, the annual export $ 200 million or more.
According to incomplete statistics, in 2010 the Group achieved operating income increased by 15.68%; profits up 18.5%; profit up 26.6%; another group of these indicators high. 'HaYao' brand value up to 16.062 billion yuan assessment, added 670 million yuan over the previous year, among the 500 brands in Asia forced. Harbin Pharmaceutical Group "perfect reconstruction," the excellent results continue to lead the national pharmaceutical industry, in the "Medicine Economic News," recently named the "2010 China top ten pharmaceutical industry's most influential enterprises" in the top of the list.
"Doing things did not flow away from the vulgar, conduct dare to compete with the ancients ', with the advantage of independent innovation, Harbin Pharmaceutical Group from the" innovative world-class new HaYao' grand strategic objectives of getting closer.